Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

被引：149

作者：

Holzer, Philipp ^{[1
]}

Masuya, Keiichi ^{[1
]}

Furet, Pascal ^{[1
]}

Kallen, Joerg ^{[1
]}

Valat-Stachyra, Therese ^{[1
]}

Ferretti, Stephane ^{[1
]}

Berghausen, Joerg ^{[1
]}

Bouisset-Leonard, Michele ^{[1
]}

Buschmann, Nicole ^{[1
]}

Pissot-Soldermann, Carole ^{[1
]}

Rynn, Caroline ^{[1
]}

Ruetz, Stephan ^{[1
]}

Stutz, Stefan ^{[1
]}

Chene, Patrick ^{[1
]}

Jeay, Sebastien ^{[1
]}

Gessier, Francois ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2015年 / 58卷 / 16期

关键词：

P53-MDM2; INTERACTION; ANTAGONISTS; PATHWAY;

D O I：

10.1021/acs.jmedchem.5b00810

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. This article provides an overview of the discovery of this new clinical p53:MDM2 inhibitor. The following aspects are addressed: mechanism of action, scientific rationale, binding mode, medicinal chemistry, pharmacokinetic and pharmacodynamic properties, and in vivo pharmacology/toxicology in preclinical species.

引用

页码：6348 / 6358

页数：11

共 23 条

[21] TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)
Wang, Xiaoli
Davis, Andrew
Su, Xiaoping
Muftuoglu, Muharrem
Krejsa, Cecile
Mascarenhas, John
Andreeff, Michael
Hoffman, Ronald
[J]. BLOOD, 2023, 142
[22] Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation
Coutre, Steven E.
Leonard, John P.
Barrientos, Jacqueline C.
De Vos, Sven
Flinn, Ian
Furman, Richard R.
Brown, Jennifer R.
Wagner-Johnston, Nina
Benson, Don M., Jr.
Schreeder, Marshall T.
Sharman, Jeff P.
Boyd, Thomas
Spurgeon, Stephen
Zelenetz, Andrew D.
Lamanna, Nicole
Kipps, Thomas J.
Kahl, Brad S.
Bello, Celeste M.
Burger, Jan A.
Rai, Kanti R.
Dansey, Roger
Kim, Yeonhee
Holes, Leanne M.
Lazarov, Mirella
Dubowy, Ronald L.
O'Brien, Susan M.
[J]. BLOOD, 2013, 122 (21)
[23] Discovery of clinical candidate methyl (5-(6-((4(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors
Xiang, Haoyue
Wang, Xiang
Chen, Yanhong
Zhang, Xi
Chen, Yi
Tan, Cun
Wang, Yi
Ding, Jian
Meng, Ling-Hua
Yang, Chunhao
[J]. CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 →